Business Context and Reporting Period
Alignment Healthcare, Inc. filed a Form 8-K dated December 23, 2021, with the report signed on December 27, 2021. The filing primarily addresses board appointments and related Regulation FD disclosure; it does not report operating or financial results for a fiscal period.
Key Financial and Governance Information
- The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating metrics.
- The Board of Directors increased from nine to eleven members.
- Jody Bilney and Yon Yoon Jorden were elected as independent directors, effective January 1, 2022.
- Ms. Bilney was elected as a Class II director with a term expected to expire at the 2023 annual meeting.
- Ms. Jorden was elected as a Class III director with a term expected to expire at the 2024 annual meeting.
- Each director will receive a $400,000 commencement restricted stock unit award vesting annually over three years, a $200,000 annual restricted stock unit award vesting on the first anniversary of the grant date, and a $50,000 annual cash retainer.
Material Changes Versus the Prior Comparable Period
The filing does not present a prior-period financial comparison. The material change disclosed is the expansion of the Board from nine to eleven directors through the appointments of Ms. Bilney and Ms. Jorden.
Outlook, Risks, Contingencies, and Unusual Items
- No financial guidance, operating outlook, material risk update, or contingency is disclosed.
- The Board had not determined committee assignments for the new directors as of the filing.
- The company reported no related-party transactions involving either director or their immediate families requiring disclosure under Item 404(a) of Regulation S-K.
- The appointments were not made pursuant to any arrangement or understanding with another person.
- The directors will enter into standard indemnification agreements and will be covered by the company’s directors’ and officers’ insurance policy.
Investor Verification Items
- Verify the effective date of January 1, 2022 and the applicable director terms.
- Assess the potential dilution and compensation expense associated with the restricted stock unit awards.
- Confirm subsequent committee assignments and any later changes to board composition.
- Review Exhibit 99.1, the December 27, 2021 press release, for any additional biographical or governance information.